RuncheyResearch
Back to Forecasting

GH Forecast Markets

Guardant Health Inc.

7
Active Markets
50%
Avg Probability
Price Above Value
Apr 8, 2026

Our prediction ensemble identifies elevated risk at current levels.

7 markets analyzedConfidence: MEDIUM
Read Full Thesis

All Markets

7 markets

Will Shield blood test volume reach 210,000+ tests in FY2026?

Active
48%
Likely No
94% agreement
Feb 28, 2027
IG: 0.80

Will Shield receive ACS guideline inclusion by year-end 2026?

Active
45%
Likely No
92% agreement
Jan 15, 2027
IG: 0.80

Will GH total revenue exceed $900M in FY2026?

Active
55%
Likely Yes
94% agreement
Feb 28, 2027
IG: 0.64

Will GH core oncology business generate positive FCF in FY2026?

Active
58%
Likely Yes
96% agreement
Feb 28, 2027
IG: 0.64

Will Guardant360 ADLT FDA submission occur by year-end 2026?

Active
60%
Likely Yes
94% agreement
Jan 15, 2027
IG: 0.48

Will GH total company cash burn be below $200M in FY2026?

Active
42%
Likely No
94% agreement
Feb 28, 2027
IG: 0.48

Will Quest co-promotion contribute materially to Shield volumes by H2 2026?

Active
40%
Likely No
92% agreement
Jan 15, 2027
IG: 0.48

Resolution Timeline

Jan 15, 2027
Will Shield receive ACS guideline inclusion by year-end 2026?
Prediction: 45%
Jan 15, 2027
Will Guardant360 ADLT FDA submission occur by year-end 2026?
Prediction: 60%
Jan 15, 2027
Will Quest co-promotion contribute materially to Shield volumes by H2 2026?
Prediction: 40%
Feb 28, 2027
Will Shield blood test volume reach 210,000+ tests in FY2026?
Prediction: 48%
Feb 28, 2027
Will GH total revenue exceed $900M in FY2026?
Prediction: 55%
Feb 28, 2027
Will GH core oncology business generate positive FCF in FY2026?
Prediction: 58%
Feb 28, 2027
Will GH total company cash burn be below $200M in FY2026?
Prediction: 42%